Dirk M Zajonc

List of Publications by Year in Descending Order

81 papers	4,321 citations	33 h-index	65 g-index
86 ext. papers	4,824 ext. citations	9.1 avg, IF	5.05 L-index

#	Paper	IF	Citations
81	Molecular Characterization of the Native (Non-Linked) CD160–HVEM Protein Complex Revealed by Initial Crystallographic Analysis. *Crystals*, **2021**, 11, 820	2.3	
80	Unconventional Peptide Presentation by Classical MHC Class I and Implications for T and NK Cell Activation. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	1
79	Catching a complex for optimal signaling. *Journal of Biological Chemistry*, **2019**, 294, 13887-13888	5.4	1
78	Structure of human cytomegalovirus UL144, an HVEM orthologue, bound to the B and T cell lymphocyte attenuator. *Journal of Biological Chemistry*, **2019**, 294, 10519-10529	5.4	4
77	A molecular switch in mouse CD1d modulates natural killer T cell activation by α-galactosylsphingamides. *Journal of Biological Chemistry*, **2019**, 294, 14345-14356	5.4	
76	Structural basis of NKT cell inhibition using the T-cell receptor-blocking anti-CD1d antibody 1B1. *Journal of Biological Chemistry*, **2019**, 294, 12947-12956	5.4	
75	Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d. *Frontiers in Immunology*, **2019**, 10, 2355	8.4	4
74	Evolution of differential 4-1BB signaling in Human and Murine immune system. *FASEB Journal*, **2019**, 33, 461.3	0.9	0
73	Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin. *Nature Immunology*, **2019**, 20, 1644-1655	19.1	16
72	An Pipeline Identifying an HLA-A02:01 KRAS G12V Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients. *Frontiers in Immunology*, **2019**, 10, 2572	8.4	26
71	4"-O-Alkylated α-Galactosylceramide Analogues as iNKT-Cell Antigens: Synthetic, Biological, and Structural Studies. *ChemMedChem*, **2019**, 14, 147-168	3.7	10
70	Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding. *Journal of Biological Chemistry*, **2019**, 294, 1831-1845	5.4	10
69	High-Affinity Bent β2 Integrin Molecules in Arresting Neutrophils Face Each Other through Binding to ICAMs In cis. *Cell Reports*, **2019**, 26, 119-130.e5	10.6	28
68	Self-glycerophospholipids activate murine phospholipid-reactive T cells and inhibit iNKT cell activation by competing with ligands for CD1d loading. *European Journal of Immunology*, **2019**, 49, 242-254	6.1	3
67	Restriction of Human Cytomegalovirus Infection by Galectin-9. *Journal of Virology*, **2019**, 93,	6.6	13
66	A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense. *Nature Communications*, **2018**, 9, 525	17.4	57
65	Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier. *Journal of Biological Chemistry*, **2018**, 293, 9958-9969	5.4	16

64	CD1c caves in on lipids. *Nature Immunology*, **2018**, 19, 322-324	19.1	1
63	Characterization of murine antibody responses to vaccinia virus envelope protein A14 reveals an immunodominant antigen lacking of effective neutralization targets. *Virology*, **2018**, 518, 284-292	3.6	1
62	Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling. *Journal of Biological Chemistry*, **2018**, 293, 1317-1329	5.4	24
61	Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8. *Journal of Biological Chemistry*, **2018**, 293, 390-401	5.4	1
60	Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01: BREAKING CONFINEMENT. *Journal of Biological Chemistry*, **2017**, 292, 5262-5270	5.4	36
59	Autoreactivity to Sulfatide by Human Invariant NKT Cells. *Journal of Immunology*, **2017**, 199, 97-106	5.3	11
58	Regulatory T Cell-Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9. *Journal of Immunology*, **2017**, 199, 2721-2728	5.3	28
57	Galactosylsphingamides: new □GalCer analogues to probe the FRpocket of CD1d. *Scientific Reports*, **2017**, 7, 4276	4.9	8
56	Crystal structure of Qa-1a with bound Qa-1 determinant modifier peptide. *PLoS ONE*, **2017**, 12, e0182296	3.7	4
55	Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove. *ELife*, **2016**, 5,	8.9	55
54	The CD1 family: serving lipid antigens to T cells since the Mesozoic era. *Immunogenetics*, **2016**, 68, 561-76	3.2	18
53	Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox. *Journal of Virology*, **2016**, 90, 4334-4345	6.6	10
52	Structure of an □Helical Peptide and Lipopeptide Bound to the Nonclassical Major Histocompatibility Complex (MHC) Class I Molecule CD1d. *Journal of Biological Chemistry*, **2016**, 291, 10677-83	5.4	9
51	A Novel Glycolipid Antigen for NKT Cells That Preferentially Induces IFN-□Production. *Journal of Immunology*, **2015**, 195, 924-33	5.3	23
50	Lipid and Carbohydrate Modifications of □Galactosylceramide Differently Influence Mouse and Human Type I Natural Killer T Cell Activation. *Journal of Biological Chemistry*, **2015**, 290, 17206-17	5.4	14
49	Recognition of Microbial Glycolipids by Natural Killer T Cells. *Frontiers in Immunology*, **2015**, 6, 400	8.4	47
48	Synthesis of C-5? and C-6?-modified □GalCer analogues as iNKT-cell agonists. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 3175-82	3.4	10
47	Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer. *PLoS Pathogens*, **2015**, 11, e1005148	7.6	11

46	The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian -linked glycosylceramides. *Immunity*, **2014**, 41, 543-54	32.3	170
45	Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. *Journal of Experimental Medicine*, **2014**, 211, 1433-48	16.6	86
44	The structure of cytomegalovirus immune modulator UL141 highlights structural Ig-fold versatility for receptor binding. *Acta Crystallographica Section D: Biological Crystallography*, **2014**, 70, 851-62		5
43	Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease. *Journal of Immunology*, **2014**, 193, 4580-9	5.3	43
42	Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein. *Journal of Virology*, **2014**, 88, 11339-55	6.6	22
41	Murine anti-vaccinia virus D8 antibodies target different epitopes and differ in their ability to block D8 binding to CS-E. *PLoS Pathogens*, **2014**, 10, e1004495	7.6	7
40	Using a combined computational-experimental approach to predict antibody-specific B cell epitopes. *Structure*, **2014**, 22, 646-57	5.2	50
39	Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. *Cell Host and Microbe*, **2013**, 13, 324-35	23.4	75
38	Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions. *PLoS Pathogens*, **2013**, 9, e1003224	7.6	32
37	The bovine CD1D gene has an unusual gene structure and is expressed but cannot present -galactosylceramide with a C26 fatty acid. *International Immunology*, **2013**, 25, 91-8	4.9	15
36	Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection. *Journal of Immunology*, **2013**, 191, 2916-25	5.3	32
35	Helicobacter pylori cholesteryl -glucosides contribute to its pathogenicity and immune response by natural killer T cells. *PLoS ONE*, **2013**, 8, e78191	3.7	43
34	Type II natural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens. *Nature Immunology*, **2012**, 13, 851-6	19.1	102
33	Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells. *Immunological Reviews*, **2012**, 250, 167-79	11.3	61
32	Crystal structures of bovine CD1d reveal altered -GalCer presentation and a restricted A pocket unable to bind long-chain glycolipids. *PLoS ONE*, **2012**, 7, e47989	3.7	13
31	Structural and biochemical characterization of the vaccinia virus envelope protein D8 and its recognition by the antibody LA5. *Journal of Virology*, **2012**, 86, 8050-8	6.6	18
30	Structural and functional characterization of a novel nonglycosidic type I NKT agonist with immunomodulatory properties. *Journal of Immunology*, **2012**, 188, 2254-65	5.3	22
29	Structural basis for the recognition of C20:2--GalCer by the invariant natural killer T cell receptor-like antibody L363. *Journal of Biological Chemistry*, **2012**, 287, 1269-78	5.4	21

28	NKT cell ligand recognition logic: molecular basis for a synaptic duet and transmission of inflammatory effectors. *Journal of Immunology*, **2011**, 187, 1081-9	5.3	37
27	Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. *Nature Immunology*, **2011**, 12, 966-74	19.1	259
26	Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. *EMBO Journal*, **2011**, 30, 2294-305	13	90
25	Glycolipids that elicit IFN-biased responses from natural killer T cells. *Chemistry and Biology*, **2011**, 18, 1620-30		33
24	Galactose modified iNKT cell agonists stabilised by a novel structural modification of CD1d lead to marked Th1 polarisation in vivo. *Annals of the Rheumatic Diseases*, **2011**, 70, A53-A53	2.4	
23	Cutting edge: structural basis for the recognition of linked glycolipid antigens by invariant NKT cells. *Journal of Immunology*, **2011**, 187, 2079-83	5.3	53
22	Cardiolipin binds to CD1d and stimulates CD1d-restricted T cells in the normal murine repertoire. *Journal of Immunology*, **2011**, 186, 4771-81	5.3	87
21	Unique interplay between sugar and lipid in determining the antigenic potency of bacterial antigens for NKT cells. *PLoS Biology*, **2011**, 9, e1001189	9.7	42
20	Structural basis for lipid-antigen recognition in avian immunity. *Journal of Immunology*, **2010**, 184, 2504-11	5.3	21
19	Crystal structure of bovine CD1b3 with endogenously bound ligands. *Journal of Immunology*, **2010**, 185, 376-86	5.3	15
18	Lipid binding orientation within CD1d affects recognition of Borrelia burgorferi antigens by NKT cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 1535-40	11.5	84
17	Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. *Journal of Immunology*, **2010**, 184, 141-53	5.3	100
16	The V14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode. *Journal of Experimental Medicine*, **2010**, 207, 2383-93	16.6	77
15	Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells. *Immunological Reviews*, **2009**, 230, 188-200	11.3	36
14	Crystal structures of mouse CD1d-iGb3 complex and its cognate Valpha14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. *Journal of Molecular Biology*, **2008**, 377, 1104-16	6.5	88
13	The crystal structure of avian CD1 reveals a smaller, more primordial antigen-binding pocket compared to mammalian CD1. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 17925-30	11.5	28
12	CD1 mediated T cell recognition of glycolipids. *Current Opinion in Structural Biology*, **2007**, 17, 521-9	8.1	49
11	Structural characterization of mycobacterial phosphatidylinositol mannoside binding to mouse CD1d. *Journal of Immunology*, **2006**, 177, 4577-83	5.3	65

10	Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 3972-7	11.5	127
9	Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. *Nature Immunology*, **2006**, 7, 978-86	19.1	521
8	Molecular mechanism of lipopeptide presentation by CD1a. *Immunity*, **2005**, 22, 209-19	32.3	112
7	CD1 assembly and the formation of CD1-antigen complexes. *Current Opinion in Immunology*, **2005**, 17, 88-94	7.8	29
6	T-cell activation by lipopeptide antigens. *Current Opinion in Immunology*, **2005**, 17, 222-9	7.8	20
5	Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. *Nature Immunology*, **2005**, 6, 810-8	19.1	267
4	Anatomy of CD1-lipid antigen complexes. *Nature Reviews Immunology*, **2005**, 5, 387-99	36.5	154
3	Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. *Journal of Experimental Medicine*, **2005**, 202, 1517-26	16.6	170
2	T cell activation by lipopeptide antigens. *Science*, **2004**, 303, 527-31	33.3	220
1	Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. *Nature Immunology*, **2003**, 4, 808-15	19.1	201